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Multidetector CTAbstract Introduction: Systemic lupus erythematosus (SLE) is a chronic inﬂammatory autoim-
mune disease that affects mainly young women. The incidence of myocardial infarction is 5 times
higher in SLE patients than in the general population.
Aim of the work: The aim of our study was to assess the frequency and extent of coronary artery
calciﬁcation as measured by multidetector computed tomography (CT) in SLE patients and to iden-
tify the associated variables.
Patients and methods: Thirty SLE patients and 30 matched healthy controls were included in the
study. Patients were not known to have atherosclerosis. Patients and controls were subjected to full
history taking, clinical examination, laboratory investigations including complete blood count,
urine analysis, serum urea, creatinine, homocysteine, triglycerides, total cholesterol, high and low
density lipoproteins. Multi detector CT study of the coronaries was performed.
Results: Coronary calciﬁcation was detected in 4 (13.3%) of the patients and none of the
control. The homocysteine level was signiﬁcantly higher in the patients (13.42 ± 5.33 lmol/L)
compared to the control (9.39 ± 1.48 lmol/L) (p= 0.002). The calcium score was
42 ± 111.09 in the patients and zero in the control. The calciﬁcation score of the 4 patients
was between 101 and 400. Patients with calciﬁcation had signiﬁcantly higher cholesterol, triglyc-
erides and homocysteine levels (p< 0.0001, p= 0.032 and p= 0.002, respectively). The calcium
score signiﬁcantly correlated with the serum cholesterol (r= 0.54, p= 0.002) and homocysteine
level (r= 0.78, p= 0.001).
S44 T.S. Heshmat et al.Conclusion: Premature coronary artery calciﬁcation is more common in SLE patients than in the
general population. Subclinical atherosclerosis in SLE is associated with traditional risk factors like
hypercholesterolemia and hypertriglyceridemia as well as increased homocysteine level.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
SLE is an autoimmune disorder characterized by multisystem
microvascular inﬂammation with the generation of autoanti-
bodies. Although the speciﬁc cause of SLE is unknown, multi-
ple factors are associated with the development of the disease,
including genetic, racial, hormonal, and environmental factors
[1,2]. Several key player factors play a signiﬁcant role in the
pathogenesis of SLE such as cytokine overproduction [3,4],
oxidative stress [5] and apoptosis [6]. Comorbidities as meta-
bolic syndrome [7], dyslipidemia and atherosclerosis [8] could
lead to functional disability, impaired quality of life and signif-
icantly affect the disease activity and damage.
The increase in the development of atherosclerosis has
been reported in different rheumatic diseases as rheumatoid
arthritis [9], osteoarthritis [10], Behc¸ets disease [11], systemic
sclerosis [12] and SLE [7,13,14] among Egyptian patients.
Coronary vessels of SLE patients have the usual atheroscle-
rotic plaque. Not all cardiovascular events are due to large
obstructive plaques. Smaller ones susceptible to rupture
can cause occlusive events too. Acute coronary syndromes
are caused by acute disruption of unstable atheroma
and SLE patients are more likely to have vulnerable plaque
rupture [13].
Coronary calciﬁcation is strongly associated with the prog-
nosis. Indeed, the extent of coronary atherosclerosis (total cal-
cium score) is the most powerful predictor of subsequent or
recurrent cardiac events. This was true in the early days when
calcium was detected with ﬂuoroscopy and conventional CT.
When electron beam CT calcium scores became available,
the prognostic value of coronary calciﬁcation was again
afﬁrmed. The higher the calcium score, the worse the prognosis
[15,16].
A systematic review which included 28 studies found that
the risk of cardiovascular disease (CVD) (which included
myocardial infarction, cerebrovascular disease, and peripheral
vascular disease) among SLE patients at least doubled when
compared with the general population. Traditional CVD risk
factors, along with disease duration and activity, appear to fur-
ther increase the risk. Younger SLE patients were found to
have a greatest relative risk of a CVD compared with their
healthy counterparts, but the absolute risk was higher in older
patients [17].
The aim of our study was to assess the frequency and extent
of coronary artery calciﬁcation as measured by multidetector
computed tomography (CT) in SLE patients and to identify
the associated variables.2. Patients and methods
This study was carried out to evaluate premature coronary
atherosclerosis in patients with SLE and measure thecalciﬁcation within the coronary vessels by using Electron
Beam CT Scan. Thirty patients fulﬁlling the Systemic Lupus
International Collaborating Clinics classiﬁcation criteria for
SLE [18] and 30 (age and sex matched) normal control subjects
were recruited for this study. Patients were recruited from
internal medicine and rheumatology outpatient clinic. The
study was approved by the local university ethics committee
and the study performed in accordance with the ethical stan-
dards of the 1964 Helsinki declaration. All patients gave their
informed consent prior to their inclusion in the study.
All the patients and control subjects were subjected to full
history taking, clinical examination and ECG. Blood pressure
was determined as the average of two measurements obtained
5 min apart after subjects had rested quietly in the supine posi-
tion for 10 min. Subjects were considered to have hypertension
if they were taking anti hypertensive agents or if they had a
systolic blood pressure (SBP) of at least 140 mmHg or a dias-
tolic BP of at least 90 mmHg. Laboratory investigations per-
formed included complete blood count (CBC), urine analysis,
serum urea, creatinine, triglycerides, total cholesterol, high
and low density lipoproteins. The serum homocysteine level
was assessed. Multidetector CT study of the coronaries was
performed. All SLE patients received different doses of
Prednisone ranging from 5 to 15 mg per day. All SLE patients
were not diabetic. Patients and control subjects with history of
CVD (previous stroke, myocardial infarction, angina or
ischemic changes in ECG) were excluded.
2.1. Imaging procedures
All subjects underwent imaging with an Imatron C-150 scanner
(Imatron). Imaging was performed with a 100-ms scanning time
and a single-slice thickness of 3 mm. A total of 40 slices were
obtained during single breath-holding periods. Tomographic
imaging was electrocardiographically triggered at 60% of the
interval between R waves. All areas of calciﬁcation within the
borders of a coronary artery with a minimal attenuation of
130 Hounsﬁeld units were computed. Subjects were included
in this study only if complete data were available from their
scans, without misregistration of slices owing to artifacts of
motion, respiration, or asynchronous electrocardiographic trig-
gering. A calciﬁed coronary plaque was considered present if at
least three consecutive pixels were measured (voxel size,
1.03 mm3). The acquired images were reviewed at the core elec-
tron-beam CT laboratory on a NetraMD workstation
(ScImage).
2.2. Calculation of calcium scores
The degree of coronary artery calciﬁcation was calculated by
Agatston et al., [19]. Calcium score of zero represents the
absence of detectable calcium, whereas a score of 1–100 indi-
cates mild degree of calciﬁcation, score of 101–400 indicates
Table 2 Correlation of calcium score with lipid proﬁle and
homocysteine in SLE patients.
Variable r p
Cholesterol (mg/dl) 0.54 0.002
HDL (mg/dl) 0.02 0.9
LDL (mg/dl) 0.36 0.054
Triglycerides (mg/dl) 0.29 0.13
Homocysteine (lmol/L) 0.78 0.001
HDL: high density lipoprotein; LDL: low density lipoprotein. Bold
values are signiﬁcant at p< 0.05.
Table 3 Comparison of data between SLE patients with and
without calciﬁcation.
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cates the presence of extensive coronary artery calciﬁcation.
The sum of the scores for all arterial lesions provides an overall
score for each subject. The correlation between this score and
other variables, such as coronary risk factors was determined.
Statistical analysis: The data were coded and entered using
the statistical package SPSS version 15. The data were summa-
rized using descriptive statistics: mean, standard deviation,
minimal and maximum values for quantitative variables and
number and percentage for qualitative values. Statistical differ-
ences between groups were tested using Chi Square test for
qualitative variables, independent sample t test for quantitative
normally distributed variables while Nonparametric Mann
Whitney test was used for quantitative variables which are
not normally distributed. Correlations were done to test for
linear relations between variables.Variable Systemic lupus erythematosus patients
(n= 30)





Age (years) 36.5 ± 5.8 31.4 ± 4.8 0.06
SBP (mmHg) 127.5 ± 22.2 132.3 ± 22.3 0.7
DBP (mmHg) 82.5 ± 12.6 82.9 ± 13.7 0.96
Cholesterol (mg/dl) 278.3 ± 7.1 188.5 ± 50.8 <0.0001
HDL (mg/dl) 51.3 ± 13 53.5 ± 8.5 0.65
LDL (mg/dl) 131.8 ± 28.2 101.8 ± 28.3 0.06
Triglycerides (mg/
dl)
252.3 ± 47.9 166.5 ± 98.8 0.03
Creatinine (mg/dl) 1.1 ± 0.2 0.8 ± 0.28 0.14
Urea (mg/dl) 48.5 ± 13.7 39.2 ± 18.4 0.18
Homocysteine
(lmol/L)
23.8 ± 2.2 11.8 ± 3.6 0.002
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL:
high density lipoprotein; LDL: low density lipoprotein. Bold values
are signiﬁcant at p< 0.05.3. Results
The study included 30 SLE patients and 30 age and sex
matched controls. Table 1 shows demographic and laboratory
data of patients and control groups. All the values were com-
parable between the patients and control except for the serum
homocysteine level and calcium score which were signiﬁcantly
higher in the SLE patients (p= 0.002 and p= 0.04, respec-
tively). The electrocardiogram (ECG) was normal in all the
patients and controls.
In the SLE patients, coronary artery calciﬁcation detected
by multidetector CT was found in 4 patients (13.3%) and they
had calciﬁcation scores between 101 and 400. No calciﬁcation
was detected in the controls.
Table 2 shows the correlation of calcium score with the
lipid proﬁle and homocysteine in SLE patients. A comparison
of clinical and laboratory data between SLE patients with and
without calciﬁcation is shown in Table 3.Table 1 Demographic and laboratory data of systemic lupus







Age (years) 32.1 ± 5.1 32.3 ± 5.4
Female:Male 19:11 19:11
Smokers n (%) 7 (23.3) 8 (26.7)
SBP (mmHg) 131.6 ± 21.98 125.8 ± 18.3
DBP (mmHg) 82.8 ± 13.4 82.3 ± 10.4
Hemoglobin (g/dl) 10.1 ± 1.4 12.1 ± 1.2
TLC (·103/mm3) 5.6 ± 1.4 6.4 ± 1.01
Platelets (·103/mm3) 250.1 ± 78.3 229.1 ± 51.04
Creatinine (mg/dl) 0.8 ± 0.3 0.8 ± 0.2
Urea (mg/dl) 40.4 ± 17.9 25.9 ± 3.1
Cholesterol (mg/dl) 200.5 ± 56.5 178.9 ± 48.9
HDL (mg/dl) 53.2 ± 8.99 50.7 ± 14.5
LDL (mg/dl) 105.8 ± 29.7 94.97 ± 24.54
Triglycerides (mg/dl) 177.97 ± 97.7 136.1 ± 36.6
Homocysteine (lmol/L) 13.4 ± 5.3 9.4 ± 1.5
Calcium score 42 ± 111.1 Zero
TLC: total leucocytic count; SBP: systolic blood pressure; DBP:
diastolic blood pressure; HDL: high density lipoprotein; LDL: low
density lipoprotein.4. Discussion
SLE is a chronic inﬂammatory autoimmune disease that affects
mainly young women, a group usually free of atherosclerosis.
The incidence of myocardial infarction is ﬁve times as high in
patients with lupus as in the general population [20].
Coronary artery atherosclerosis can be detected non-invasively
with the use of electron beam computed tomography (CT). The
extent of coronary artery calciﬁcation in CT correlates with
ﬁndings on coronary angiography and with the extent of
atherosclerosis in pathological specimens and is predictive of
future cardiac events [21].
In our study, we found that the coronary calciﬁcation was
detected by multidetector CT in 4 (13.3%) SLE patients but no
calciﬁcation was detected in control subjects. None of the 4
patients had calcium score greater than 400, the calcium score
ranged 101–400 indicating a moderate degree of calciﬁcation,
while in another study [22], the frequency of coronary calciﬁ-
cation was higher, it was detected in 31% of SLE patients
and 9% of the control, and the degree of calciﬁcation was
higher; 15% had calcium score greater than 400. These differ-
ences in frequency and degree of calciﬁcation may be due to
different factors as race, diet, genetic and environmental fac-
tors. Our results were in contrast to Kakuta et al. [23] who
S46 T.S. Heshmat et al.found that coronary artery calciﬁcation was similar in patients
and control groups.
In the present study, there was a tendency to a higher degree
of calciﬁcation in patients with older age. This was similarly
reported in other studies [24–26]. We also found that the level
of cholesterol (200.5 ± 56.5 mg/dl) in SLE patients was higher
than in the control (178.9 ± 48.9) but with no statistical signif-
icance. However, the cholesterol level was signiﬁcantly higher
in SLE patients with calciﬁcation (278.3 ± 7.1 mg/dl) com-
pared to those without (188.5 ± 50.8 mg/dl) (p< 0.0001).
The cholesterol level also signiﬁcantly correlated with calcium
score (p= 0.002). It has been found that in SLE patients with
persistent hypercholesterolemia followed up for a mean of
12 years, 24% developed a new CVD event compared with only
3% of those with normal cholesterol levels [20,24].
We also found that the level of triglycerides
(177.97 ± 97.7 mg/dl) in patients with SLE was higher than
in control (136.1 ± 36.6 mg/dl). The level was higher in patients
with calciﬁcation (252.3 ± 47.9 mg/dl) than in those without
(166.5 ± 98.8 mg/dl) (p= 0.03).
Regarding homocysteine, its level in SLE patients
(13.4 ± 5.33 lmol/L) was higher than control
(9.4 ± 1.5 lmol/L) (p= 0.002). Homocysteine signiﬁcantly
correlated with calcium score (p= 0.001). This is similar to
the results of VonFeldt et al. andAsanuma et al. who found that
in SLE patients the level of homocysteine was higher than con-
trol and the coronary artery calciﬁcation (detected by electron
beam computed tomography) was associated with a higher
homocysteine concentration [22,27]. The disease activity and
damage score were not included in this study and both may be
well thought-out in further prospective researches.
In the current study, hypertension did not correlate with the
calcium score in SLE patients; this ﬁnding is not similar to the
study of Kiani et al., who found that the hypertension was
correlated with coronary calcium [25].
In conclusion, premature coronary artery calciﬁcation is
more common in SLE patients than in the general population.
Subclinical atherosclerosis in SLE is associated with tradi-
tional risk factors like hypercholesterolemia and hypertriglyc-
eridemia as well as increased homocysteine level.Conﬂict of interest
None declared.
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